Announced Thu, 27 Aug · 17:05 IST
Annual Report FY25-26: Revenue Rs345.4cr, EBITDA up Six-Fold, Loss Narrows 37.5%
BPLPHARMA · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Price reaction · full curve 14 horizons · vs prior close
+2.9%1-day move
₹1495.90
prior close
₹1578.20
base price
After-mkt
timing
5m10m15m30m1D2D3D4D5D7D15D1M2M3M
-2.0-1.7-1.7-1.8+2.9+0.9+1.5+1.6+1.7+5.1+3.3———
Up moveDown movePending
AI summary
Consolidated revenue rose 1.5% to Rs345.4cr. EBITDA jumped nearly 6x to Rs15.8cr (margin 4.6% versus 0.8%). Loss after tax narrowed 37.5% to Rs27.3cr. Operating cash flow turned positive at Rs38.4cr. Borrowings cut to Rs146.1cr from Rs180.2cr. Standalone PAT Rs16cr. Innoxel revenue grew 174%, turned EBITDA-positive. Dividend Rs1 per share.
Likely market impact
Improved profitability, debt reduction and positive cash flow signal turnaround; standalone revenue dip and consolidated loss remain concerns.